EOS Clinical Trials

220 recruitingLast updated: July 25, 2026

There are 220 actively recruiting eos clinical trials across 45 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Boston, Massachusetts, United States, Philadelphia, Pennsylvania, United States, Atlanta, Georgia, United States. Updated daily from ClinicalTrials.gov.


EOS Trials at a Glance

220 actively recruiting trials for eos are listed on ClinicalTrialsFinder across 6 cities in 45 countries. The largest study group is Phase 2 with 51 trials, with the heaviest enrollment activity in Boston, Philadelphia, and Atlanta. Lead sponsors running eos studies include National Institute of Allergy and Infectious Diseases (NIAID), St. Jude Children's Research Hospital, and Children's Hospital Medical Center, Cincinnati.

Treatments under study

About EOS Clinical Trials

Looking for clinical trials for EOS? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new EOS trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about EOS clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 220 trials

Recruiting
Phase 2Phase 3

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

Metastatic OsteosarcomaHigh Grade OsteosarcomaLocalized Osteosarcoma+1 more
National Cancer Institute (NCI)1,122 enrolled202 locationsNCT05691478
Recruiting
Phase 1Phase 2

Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma

SarcomaOsteosarcoma
H. Lee Moffitt Cancer Center and Research Institute74 enrolled4 locationsNCT07725380
Recruiting
Phase 3

A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases

Eosinophilic Granulomatosis With Polyangiitis (EGPA)Hypereosinophilia Syndrome (HES)
AstraZeneca14 enrolled15 locationsNCT06512883
Recruiting
Phase 1

NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma

Refractory OsteosarcomaRefractory NeuroblastomaRelapsed Neuroblastoma+1 more
Baylor College of Medicine27 enrolled1 locationNCT07211737
Recruiting

A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression

EosinophiliaHypereosinophilic Syndrome
National Institute of Allergy and Infectious Diseases (NIAID)50 enrolled1 locationNCT00091871
Recruiting
Phase 2

Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis

Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis
CSL Behring84 enrolled99 locationsNCT07332091
Recruiting

Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia

Immune System DiseasesEosinophiliaHelminthiasis+2 more
National Institute of Allergy and Infectious Diseases (NIAID)800 enrolled1 locationNCT00001406
Recruiting
Not Applicable

The Esophageal String Test as a Diagnostic Screening Tool for Eosinophilic Esophagitis Among Africans With Dysphagia in Mali and the United States

eosinophilic esophagitisDysphagia
National Institute of Allergy and Infectious Diseases (NIAID)70 enrolled3 locationsNCT07027826
Recruiting
Phase 1Phase 2

Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

OsteosarcomaRecurrent OsteosarcomaWilms Tumor+5 more
National Cancer Institute (NCI)55 enrolled28 locationsNCT04616560
Recruiting
Phase 2

Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents

Hypereosinophilic Syndrome
National Institute of Allergy and Infectious Diseases (NIAID)30 enrolled1 locationNCT06477653
Recruiting
Not Applicable

Let's E.A.T.! (Eating With Assistive Technology): An Intervention to Support Children With Feeding Tubes and Tracheostomies

Children with medical complexityTracheostomyFeeding Tube+1 more
University of Chicago40 enrolled1 locationNCT06525818
Recruiting
Phase 3

Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE

eosinophilic esophagitis
Dr. Falk Pharma GmbH308 enrolled27 locationsNCT06596252
Recruiting

A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy

Severe Eosinophilic Asthma
AstraZeneca335 enrolled28 locationsNCT07214753
Recruiting
Phase 2

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

OsteosarcomaEwing Sarcoma
Milton S. Hershey Medical Center406 enrolled2 locationsNCT07321912
Recruiting
Phase 1Phase 2

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

AngiosarcomaLiposarcomaAdipocytic Neoplasm+6 more
St. Jude Children's Research Hospital139 enrolled7 locationsNCT06239272
Recruiting

Characteristics and Inflammatory Markers in Children With Eosinophilic Esophagitis (EoE)

eosinophilic esophagitis
University of California, San Diego1,500 enrolled1 locationNCT03980886
Recruiting
Phase 3

A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis

Eosinophilic Esophagitis (EoE)
Regeneron Pharmaceuticals20 enrolled11 locationsNCT07112378
Recruiting
Phase 1Phase 2

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

OsteosarcomaEwing SarcomaNeuroblastoma+2 more
Milton S. Hershey Medical Center104 enrolled22 locationsNCT06541262
Recruiting
Phase 1Phase 2

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

OsteosarcomaEwing SarcomaNeuroblastoma+4 more
Milton S. Hershey Medical Center289 enrolled12 locationsNCT06465199
Recruiting

Natural History and Genetics of Food Allergy and Related Conditions

eosinophilic esophagitisAtopic DermatitisFood allergy+1 more
National Institute of Allergy and Infectious Diseases (NIAID)1,800 enrolled1 locationNCT02504853